Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
This trial is designed to enroll postmenopausal patients with locally advanced or metastatic,
 HER2- and HR+ breast cancer not amenable to curative treatment by surgery or radiotherapy,
 and whose disease has progressed on or after prior endocrine therapy.

 Patients must undergo molecular pre-screening prior to entry.
Inclusion Criteria:

 -  Postmenopausal women with HER2-, HR+ locally advanced or metastatic breast cancer

 -  Progression on or after endocrine treatment

 -  Measureable disease as per RECIST

 -  ECOG 0, 1 or 2

 Exclusion Criteria:

 -  Evidence of CNS or leptomeningeal metastases

 -  Previous treatment with fulvestrant

 -  Previous chemotherapy for locally advanced or metastatic breast cancer

 -  Cirrhosis or chronic active/persistent hepatitis

 Other protocol-defined inclusion/exclusion criteria may apply